Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply

N Engl J Med. 2019 Sep 12;381(11):1089-1090. doi: 10.1056/NEJMc1909687.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Canagliflozin
  • Diabetes Mellitus, Type 2*
  • Diabetic Nephropathies*
  • Humans
  • Kidney
  • Sodium-Glucose Transporter 2 Inhibitors*

Substances

  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin